Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics


Corvus Pharmaceuticals, Inc. (CRVS)

Today's Latest Price: $4.00 USD

0.08 (2.04%)

Updated Oct 22 4:00pm

Add CRVS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CRVS Stock Price Chart Interactive Chart >

Price chart for CRVS

CRVS Price/Volume Stats

Current price $4.00 52-week high $6.88
Prev. close $3.92 52-week low $1.01
Day low $3.91 Volume 87,200
Day high $4.07 Avg. volume 981,853
50-day MA $3.95 Dividend yield N/A
200-day MA $3.68 Market Cap 112.14M

Corvus Pharmaceuticals, Inc. (CRVS) Company Bio


Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.


CRVS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRVS Latest Social Stream


Loading social stream, please wait...

View Full CRVS Social Stream

Latest CRVS News From Around the Web

Below are the latest news stories about Corvus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRVS as an investment opportunity.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE…

GlobeNewswire | July 30, 2020

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.“In the second quarter, we advanced each of our three clinical oncology programs, highlighted by the presentation of new data at ASCO on the identification of a refined biomarker that enriches for responding patients with renal cell cancer treated with our lead candidate, ciforadenant,” said Richard A. Miller, M.D.,  president and chief executive officer of Corvus. “Based on this data, we are planning to meet with the U.S. Food & Drug Adm...

Yahoo | July 30, 2020

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results.  The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and using the conference ID 10010533. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clin...

Yahoo | July 23, 2020

3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)

The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that these stocks are risky in nature, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Given this volatility, it can be difficult to gauge which healthcare stocks are primed to outperform. That’s where Wall Street analysts come in.Using TipRanks’ database, we identified three trading for less than $5 per sha...

Yahoo | July 20, 2020

Corvus Pharmaceuticals (CRVS) Catches Eye: Stock Jumps 8.4%

Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Yahoo | July 9, 2020

Read More 'CRVS' Stories Here

CRVS Price Returns

1-mo 2.83%
3-mo -6.76%
6-mo 49.25%
1-year 14.29%
3-year -71.43%
5-year N/A
YTD -26.47%
2019 48.23%
2018 -64.58%
2017 -27.55%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6944 seconds.